Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study

Date : 06/11/2019 @ 11:25AM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.17  -0.13 (-0.34%) @ 9:13PM

Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Roche Holding (QX) Charts.

By Colin Kellaher

 

Roche Holding AG's (ROG.EB) Genentech unit Tuesday said a phase II study of Gazyva met its primary and key secondary endpoints in adults with the kidney disorder proliferative lupus nephritis.

Genentech said Gazyva in combination with standard of care showed enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year.

Gazyva also showed improved overall renal responses and serologic markers of disease activity compared to placebo, the company said.

Genentech said there are currently no FDA-approved therapies for lupus nephritis, a potentially life-threatening condition in which patients are at high risk for progressing to end-stage renal disease or death.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 11, 2019 07:10 ET (11:10 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.